Neuroimaging of the dopamine transporter in Parkinson's disease: First study using [99mTc]-TRODAT-1 and SPECT in Brazil;Neuroimagem do transportador de dopamina na doença de Parkinson: Primeiro estudo com [99mTc]-TRODAT-1 e SPECT no Brasil

Arquivos de Neuro-Psiquiatria

Volumn 64, Issue 3 A, 2006, Pages

  Ming, Chi Shih ^a,b   Amaro Jr , Edson ^b   Ferraz, Henrique Ballalai ^a   Hoexter, Marcelo Queiroz ^a   Goulart, Fabricio Oliveira ^a   Wagner, Jairo ^b   Li, Fu Lin ^c   Ying, Kai Fu ^c   Mari, Jair Jesus ^a   De Lacerda, Acioly Luiz Tavares ^a   Tufik, Sergio ^a   Bressan, Rodrigo Affonseca ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Diagnosis; Dopamina; Dopamine transporter; Parkinson's disease; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; TRACER; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

ARTICLE; BRAZIL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG BINDING; HUMAN; MOTOR PERFORMANCE; NEUROIMAGING; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84859674188     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
3. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
4. Boulton AA, Eisenhofer G. Catecholamine metabolism: from molecular understanding to clinical diagnosis and treatment. Adv Pharmacol 1998;42:273-292.
5. Storch A, Ludolph AC, Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004;111:1267-1286.
6. Díaz F, Mena I. Early diagnosis of Parkinson disease: NeuroSPECT findings of TRODAT-1 Tc99m labeling of the Dopamine transporter (DAT). Clinical Testing. Alasbimn Journal 2(6): January 2000. http://www.alasbimnjournal.cl/ revistas/6/diaz. html.
7. 99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 2005;64:1716-1720.
8. Liu WG, Chen Y, Li B, Lu GQ, Chen SD. Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells. Neurochem Res 2004;29:2207-2214.
9. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004;45:393-401.
10. 99mTc] TRODAT-1 SPECT imaging in early Parkinson's disease. Parkinsonism Relat Disord 2004;10:375-379.
11. Meegalla SK, Plossl K, Kung MP, et al. Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J Med Chem 1997;40:9-17.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001;57(Suppl):S11-S26.
13. Bertolucci PHF, Bruck SMD, Campacci SR, Juliano Y. O mini-exame do estado mental em uma população geral: impacto da escolaridade. Arq Neuropsiquiatr 1994;52:1-7.
14. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease 1987;2:153-164.
15. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In Gillingham FJ, Donaldson IML (eds). Third Symposium on Surgery in Parkinson' Disease. Edinburgh: Livingstone, 1969:152-157.
16. Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-1456.
17. Kanyo B, Argyelan M, Dibo G, et al. Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders. Ideggyogy Sz 2003; 56:231-240.
18. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000;41:584-589.
19. Shih MC, Hoexter MQ, Andrade LAF, Bressan RA. Parkinson's disease and dopamine tranporter neuroimaging: a critical review. São Paulo Medical Journal 2006;124(2) in press.
20. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
21. 99mTc-TRODAT-1 SPECT: Parkinson gene analysis and clinical study. Parkinsonism Relat Disord 2005;11:173-180.
22. Rinne JO, Laihinen A, Lonnberg P, Marjamaki P, Rinne UK. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 1991;556:117-122.
23. Staffen W, Mair A. Unterrainer J, Trinka E, Bsteh C, Ladurner G. [123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Commun 2000;21:417-424.
24. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
25. Bressan RA, Costa DA, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs D2 receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56:31-36.
26. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.J Nucl Med 2005;46:227-232.
27. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-1143.
28. Schubert T, Volkmann J, Muller U, et al. Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease. Exp Brain Res 2002;144:8-16.
29. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005 26;64:1404-1410.
30. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
31. Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun 2005; 26:421-426.
32. 99mTc]-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med 2004;45:207-213.
33. Martinez-Martin P, Forjaz MJ, Cubo E, Frades B, de Pedro Cuesta J. Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISI-PD) Mov Disord 2006 (in press).